Absorbable Surgical Sutures Market Size & Share 2026-2035

Absorbable Surgical Sutures Market Size

The Absorbable Surgical Sutures Market was valued at USD 3.05 billion in 2025, is valued at USD 3.23 billion in 2026, and is projected to grow at a 6.5% CAGR (2026–2035) to reach USD 5.68 billion by 2035. The market encompasses synthetic and natural sutures that are biologically degraded after wound closure, including Vicryl/polyglycolic acid, PDS/polydioxanone, Monocryl/poliglecaprone, and plain and chromic gut products in monofilament and multifilament formats.

Market expansion is anchored in procedure growth and a changing consumption mix. Rising surgical capacity broadens the volume base, while migration toward ambulatory care, adoption of synthetic monofilaments, and demand for antimicrobial and knotless formats alter where sutures are procured and which configurations command formulary preference.

Report Coverage & Key Takeaways

The report assesses demand-side revenue across natural and synthetic absorbable materials, monofilament and multifilament structures, surgical applications, and hospital, ambulatory surgical center, specialty clinic, and other care settings. It evaluates five regions and their covered country markets, with attention to procedure volumes, care-site migration, regulatory requirements, sterilization economics, procurement behavior, and competitive positioning.

Absorbable Surgical Sutures Market Trends, Growth Drivers & GMI Forecast Outlook

The market's outlook reflects a durable clinical demand base, but revenue growth will be shaped by channel mix and product mix rather than procedure volume alone. Emerging-market infrastructure adds cases, ambulatory migration changes purchasing authority, and advanced formats support differentiation while regulatory and sterilization costs constrain smaller suppliers.

Key Drivers

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

The surgical-capacity deficit is commercially relevant because new operating rooms require dependable wound-closure supply chains before they can raise throughput. As lower- and middle-income health systems expand service access, material selection is increasingly moving from natural gut toward synthetic products with more consistent tensile retention, predictable absorption, and lower tissue reactivity. That conversion broadens demand across gynaecology, general surgery, and orthopaedics, rather than relying on a single elective specialty.

Ambulatory migration creates a second demand vector with different purchasing mechanics. ASC operators emphasize standardized kits, consistent availability, efficient handling, and limited stock complexity. The policy rationale behind shifting eligible cases into lower-cost sites remains strong; the Ambulatory Surgery Center Association estimates that ASC use could generate USD 84.8 billion in Medicare savings during 2025–2034 ^{[7]Ambulatory Surgery Center Association. “Medicare Savings from Use of Ambulatory Surgery Centers.” ascassociation.org}. Suppliers able to combine clinical support with tailored outpatient account coverage are therefore better positioned than those relying solely on traditional hospital contracting.

Antimicrobial coatings and knotless devices are moving the category beyond routine commodity substitution. In infection-sensitive procedures, clinical teams can evaluate these products against operating-room workflow, tissue response, and protocol objectives rather than unit cost alone. Their broader adoption depends on evidence generation, surgeon familiarity, and the ability of manufacturers to secure approvals across multiple configurations.

Key Restraints

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Ethylene oxide sterilization is integral to the supply chain for many absorbable and specialty suture formats, making the EPA rule a manufacturing-economics issue as well as an environmental compliance requirement. Capital upgrades, monitoring requirements, and potential transition-related capacity constraints are likely to be felt most sharply by companies dependent on third-party sterilization. Larger, integrated suppliers have more scope to spread those costs across broader portfolios and production volumes.

The ambulatory channel also exposes a tension between volume and revenue quality. Supply managers must balance clinical performance with tight per-case budgets, which makes premium formats harder to standardize across every procedure. Manufacturers may win consumption growth in ASCs while facing pressure on realized pricing, particularly where a conventional format meets the procedure's clinical need.

Per-SKU regulatory obligations add another barrier to global portfolio expansion. A supplier seeking broad market access must support multiple gauges, needle types, coatings, and material options through distinct regulatory pathways. The burden favors firms with established quality systems, clinical documentation, and regulatory infrastructure, while limiting the speed at which smaller entrants can assemble full-service surgical portfolios.

Absorbable Surgical Sutures Market Segment Analysis

By Material

Natural Suture

Natural sutures generated USD 244 million in 2025 and are projected to decline at a -1.4% CAGR (2026–2035).

Plain and chromic gut retain use where rapid absorption, surgeon familiarity, or procurement affordability is decisive. However, their clinical role is narrowing as hospitals favor synthetic materials with more consistent tensile retention, predictable absorption, and lower tissue reactivity.

Vicryl generated USD 1.15 billion in 2025 and is projected to reach USD 1.93 billion by 2035. Vicryl remains deeply embedded in hospital formularies because its braided construction offers dependable handling and knot security across high-volume soft-tissue applications. Its growth profile nevertheless reflects a more mature franchise as monofilament alternatives gain preference in minimally invasive and infection-sensitive procedures.

PDS (Polydioxanone)

PDS is projected to reach USD 1.52 billion by 2035 and expand at a 7.4% CAGR (2026–2035). PDS benefits from its extended support profile in fascial closure, abdominal wall repair, and selected cardiovascular and paediatric procedures. Demand is increasingly tied to higher-acuity case mix, where material performance is specified by the wound-healing requirement rather than selected as a routine substitute.

Monocryl (Poliglecaprone)

Monocryl is projected to reach USD 2.00 billion by 2035, compared with USD 884 million in 2025. The material's smooth monofilament handling, low tissue drag, and relevance to subcuticular closure make it well aligned with minimally invasive, cosmetic-sensitive, and high-throughput procedures. Antibacterial and knotless extensions further broaden its role in protocols that value procedural efficiency alongside wound-management performance.

By Structure

Monofilament

Monofilament sutures are projected to generate USD 3.11 billion by 2035 and grow at an 8.0% CAGR (2026–2035). The Absorbable Surgical Sutures Market is shifting toward monofilament structures where reduced capillarity, smoother tissue passage, and compatibility with barbed technologies matter clinically. This transition is most visible in infection-sensitive and ambulatory workflows, where surgeons seek predictable handling with fewer operational steps.

Multifilament

Multifilament sutures generated USD 1.58 billion in 2025 and are projected to reach USD 2.57 billion by 2035. Braided products retain an important role where knot security, pliability, and established surgical technique outweigh the advantages of a single-strand format. Their future position is supported by entrenched use in broad hospital applications, although clinical migration toward monofilaments limits their relative momentum.

By Application

Gynaecology

Gynaecology generated USD 854 million in 2025 and is projected to reach USD 1.59 billion by 2035. High volumes of caesarean deliveries, hysterectomies, pelvic-floor repairs, and laparoscopic procedures create a stable demand base. Material selection increasingly depends on tissue layer, closure technique, and infection-control protocol, allowing both conventional braided products and advanced monofilaments to remain relevant.

Cardiovascular applications represented a 22.0% share in 2025 and are projected to grow at a 5.9% CAGR (2026–2035). Open cardiac and vascular procedures require closely specified materials, creating meaningful switching barriers once surgeons and institutions standardize a product. Minimally invasive and transcatheter alternatives temper case growth, but they do not eliminate demand for absorbable closure in complex surgical settings.

Orthopaedic

Orthopaedic applications are projected to reach USD 1.08 billion by 2035 and grow at a 7.1% CAGR (2026–2035). Soft-tissue repair, arthroplasty closure, and ligament-related procedures favor materials with dependable handling and sustained support. The movement of selected orthopaedic cases toward ASCs strengthens demand for standardized formats that help surgical teams maintain efficiency across high procedure turnover.

Ophthalmic

Ophthalmic applications generated USD 305 million in 2025 and are projected to represent an 8.9% share in 2035. Precision needle geometry, fine-gauge construction, and low tissue drag make ophthalmic sutures a specialized category with limited direct comparability to general surgical formats. This technical specificity supports value retention even where procedure growth is more moderate in mature markets.

Neurological

Neurological applications are projected to reach USD 339 million by 2035 and grow at a 6.4% CAGR (2026–2035). Dural closure, spinal procedures, and peripheral nerve repair create a need for dependable material performance in anatomically constrained settings. The inability to remove sutures easily after surgery increases the importance of absorption characteristics and procedural consistency.

Other Surgeries

Other surgeries are projected to generate USD 980 million by 2035 and grow at a 7.3% CAGR (2026–2035). Urological, colorectal, trauma, reconstructive, and head-and-neck procedures form a diverse demand base. Their growth reflects the expanding use of synthetic absorbables in procedures where clinical teams are reassessing historic material preferences and seeking products that better suit contemporary closure techniques.

By End Use

Hospitals

Hospitals generated USD 1.89 billion in 2025 and are projected to reach USD 3.12 billion by 2035. Hospitals retain the broadest absorbable-suture requirement because they manage emergency, complex, and multispecialty surgery. Their procurement systems also support a deeper range of materials and specialty configurations than smaller outpatient sites can efficiently stock.

Ambulatory Surgical Centers (ASCs)

ASCs are projected to reach USD 1.71 billion by 2035 and grow at a 10.2% CAGR (2026–2035). ASCs are becoming a strategically distinct buying environment rather than simply an extension of hospital demand. Their emphasis on throughput, standardized procedure packs, and concise inventories increases the importance of distributor reach, outpatient-specific account management, and formats that simplify closure workflow.

Specialty Clinics

Specialty clinics generated USD 366 million in 2025 and are projected to grow at a 5.5% CAGR (2026–2035). Ophthalmic, cosmetic, dermatologic, and ambulatory specialty practices purchase against narrower procedure profiles and smaller order sizes. This favors suppliers that can offer highly specific configurations without imposing hospital-scale contracting requirements.

Other End Use

Other end-use settings are projected to represent a 4.0% share in 2035 and grow at a 6.4% CAGR (2026–2035). Academic centers, military facilities, and related institutions contribute steady consumption and can play an outsized role in the clinical diffusion of new formats. Their influence is most pronounced when novel products require surgeon training or protocol validation before broader adoption.

Absorbable Surgical Sutures Regional Analysis

North America Absorbable Surgical Sutures Analysis

North America generated USD 1.12 billion in 2025 and is projected to reach USD 1.76 billion by 2035. The Absorbable Surgical Sutures Market in North America is supported by dense surgical infrastructure, established hospital formularies, and advanced ASC networks. Mature procedure volumes place greater weight on product-mix upgrades, including antimicrobial, knotless, and specialty monofilament formats, than on simple volume expansion.

United States

The United States generated USD 1.03 billion in 2025 and is projected to reach USD 1.60 billion by 2035. The U.S. market combines large hospital demand with a rapidly evolving outpatient procurement environment. CMS expansion of ASC-eligible procedures strengthens the role of ambulatory medical directors and supply managers, while FDA clearance activity supports continued introduction of differentiated surgical closure products ^{[2]Medicare Payment Advisory Commission. “Report to the Congress: Medicare Payment Policy, Chapter 11: Ambulatory Surgery Center Services.” medpac.gov [3]U.S. Food and Drug Administration. “510(k) Premarket Notification Database.” fda.gov}.

Canada

Canada is projected to reach USD 157 million by 2035 and grow at a 5.6% CAGR (2026–2035). Provincial procurement structures concentrate purchasing authority and heighten attention to value-based contracting. Aging-related orthopaedic and cardiovascular demand supports consumption, while investment in short-stay facilities gradually expands the importance of outpatient purchasing channels.

Europe Absorbable Surgical Sutures Analysis

Europe is projected to reach USD 1.31 billion by 2035 and grow at a 4.6% CAGR (2026–2035). European growth reflects a mature clinical base in which cost control and regulatory compliance shape portfolio decisions. National procurement frameworks preserve opportunities for established brands, but they also create room for qualified alternatives that can demonstrate performance and competitive total cost.

Germany

Germany generated USD 189 million in 2025 and is projected to reach USD 291 million by 2035. Germany's dense hospital and surgical-center infrastructure supports broad use of premium materials in cardiovascular, orthopaedic, and gynaecological procedures. Group purchasing arrangements reward suppliers with reliable distribution, comprehensive portfolios, and entrenched institutional relationships.

United Kingdom

The United Kingdom is projected to reach USD 258 million by 2035 and grow at a 4.4% CAGR (2026–2035). NHS procurement standardization creates a commercially disciplined environment where framework participation and price competitiveness are critical. Surgical-site infection initiatives may favor antibacterial formats in selected protocols, but adoption depends on clear clinical and budgetary justification.

France

France generated USD 148 million in 2025 and is projected to grow at a 4.6% CAGR (2026–2035). France's public hospitals and private clinics present different sales pathways for suture suppliers. The public channel emphasizes structured procurement, whereas private providers can move more quickly toward products suited to minimally invasive and subcuticular closure techniques.

Italy

Italy is projected to reach USD 213 million by 2035, compared with USD 132 million in 2025. Regionalized healthcare purchasing creates a fragmented market in which supplier access and pricing strategy must vary by locality. Demand in northern urban surgical centers coexists with tighter public-sector purchasing conditions elsewhere, supporting a tiered competitive environment.

Spain

Spain generated USD 107 million in 2025 and is projected to reach USD 177 million by 2035. Centralized tender opportunities through regional health authorities make procurement access central to market participation. Aging-related arthroplasty demand and private-hospital activity provide complementary channels for standard and premium absorbable formats.

Netherlands

The Netherlands is projected to reach USD 133 million by 2035 and grow at a 5.1% CAGR (2026–2035). Well-funded hospitals and academic medical centers support early uptake of advanced surgical technologies. The insurance-funded provider environment can reward clinically differentiated products where benefits are clearly aligned with specialist procedural requirements.

Asia Pacific Absorbable Surgical Sutures Analysis

Asia Pacific generated USD 732 million in 2025 and is projected to reach USD 1.83 billion by 2035. The region's expansion rests on hospital development, higher surgical throughput, and progressive conversion to standardized synthetic materials. Persistent unmet surgical need across lower-income settings points to a long-duration procedure-growth opportunity, although product mix and price sensitivity differ substantially among markets ^{[1]The Lancet. “Surgical health policy 2025–35: strengthening essential services for the next decade.” thelancet.com}.

China

China generated USD 249 million in 2025 and is projected to reach USD 700 million by 2035. China's tiered hospital system offers a phased adoption pathway: leading centers often establish product specifications before newer formats diffuse to lower-tier facilities. Domestic suppliers compete strongly on cost, while international brands retain relevance in high-specification procedures and premium hospital accounts.

Japan

Japan is projected to reach USD 290 million by 2035 and accounted for 23.0% of Asia Pacific revenues in 2025. Japan remains a mature but procedure-intensive surgical market with conservative material-switching behavior. Population aging supports demand in orthopaedic, cardiovascular, and neurological specialties, while standardized hospital specifications raise the importance of clinical evidence and regulatory readiness.

India

India generated USD 146 million in 2025 and is projected to grow at a 14.2% CAGR (2026–2035). India's trajectory is driven by hospital expansion, rising access to surgery, and migration from traditional gut products to synthetic absorbables. The scale of unmet surgical need, combined with public and private capacity development, supports broad-based demand rather than a narrow premium niche ^{[1]The Lancet. “Surgical health policy 2025–35: strengthening essential services for the next decade.” thelancet.com}.

South Korea

South Korea is projected to reach USD 198 million by 2035 and grow at a 7.8% CAGR (2026–2035). South Korea combines advanced hospital organization with a receptive environment for clinical innovation. Premium antimicrobial and knotless formats can gain traction where surgeons perceive clear workflow or patient-care benefits, while medical tourism adds selective demand in elective and orthopaedic procedures.

Australia

Australia generated USD 73 million in 2025 and is projected to reach USD 139 million by 2035. Formal public tenders and a complementary private hospital sector define the Australian purchasing environment. Distribution reliability is particularly important because the market relies heavily on international supply channels across a geographically dispersed provider base.

Latin America Absorbable Surgical Sutures Analysis

Latin America is projected to reach USD 458 million by 2035 and grow at an 8.0% CAGR (2026–2035). The region combines improving surgical capacity with an ongoing shift toward synthetic absorbable products. Public procurement remains price-sensitive, while private providers create demand for recognized brands and higher-specification products, requiring suppliers to operate across sharply different value tiers.

Brazil

Brazil generated USD 111 million in 2025 and is projected to reach USD 231 million by 2035. Brazil's large public health system creates significant centralized purchasing demand, while private hospital networks sustain a separate channel for premium configurations. Strong obstetric procedure volumes reinforce the importance of gynaecological closure products within the country's overall demand mix.

Mexico

Mexico is projected to reach USD 147 million by 2035 and grow at an 8.4% CAGR (2026–2035). Demand is supported by public health-system coverage, private hospital investment, and medical-tourism activity in major urban and border-region facilities. The market provides scope for both international brands and domestic alternatives, provided suppliers can meet registration, distribution, and price requirements.

Argentina

Argentina generated USD 39 million in 2025 and is projected to grow at a 7.2% CAGR (2026–2035). Argentina's private hospitals can support demand for premium products, whereas public procurement remains highly cost conscious. Economic volatility adds complexity to supplier planning and favors companies that can balance dependable availability with locally responsive commercial terms.

Middle East & Africa Absorbable Surgical Sutures Analysis

Middle East & Africa generated USD 152 million in 2025 and is projected to grow at an 8.7% CAGR (2026–2035). Healthcare investment in Gulf markets and the gradual development of surgical capacity across African systems underpin regional demand. The large unmet surgical need across sub-Saharan Africa creates a long-term opportunity, but near-term commercial success depends on distribution reach, affordability, and dependable supply ^{[1]The Lancet. “Surgical health policy 2025–35: strengthening essential services for the next decade.” thelancet.com}.

Saudi Arabia

Saudi Arabia is projected to reach USD 144 million by 2035 and grow at a 9.2% CAGR (2026–2035). Hospital expansion and health-sector privatization broaden the country's surgical base, particularly in tertiary-care specialties. Established suppliers are advantaged by their ability to navigate registration requirements and support complex hospital accounts with premium and specialty products.

UAE

The UAE generated USD 53 million in 2025 and is projected to reach USD 121 million by 2035. The UAE's private and public providers operate with internationally oriented clinical standards and a relatively strong appetite for branded surgical supplies. Medical tourism supports incremental demand in cardiology, orthopaedics, and cosmetic procedures, where material performance and brand reputation influence procurement.

South Africa

South Africa generated USD 38 million in 2025 and is projected to grow at a 7.1% CAGR (2026–2035). South Africa's dual healthcare system divides demand between private networks that use internationally branded products and a public sector operating under tighter resource constraints. This structure concentrates commercial value in private facilities while preserving a meaningful role for cost-competitive alternatives in public tenders.

Absorbable Surgical Sutures Market Share & Competitive Landscape

The Absorbable Surgical Sutures Market share landscape is moderately concentrated, with the five leading competitors collectively holding approximately 67.0% of global revenues in 2025. Scale in regulatory affairs, manufacturing, portfolio breadth, and direct hospital access reinforces their positions, while regional and specialty suppliers compete through cost, niche expertise, and channel-specific service.

Johnson & Johnson (Ethicon)

Johnson & Johnson's Ethicon division held approximately 36.0% of the global market in 2025. Ethicon's leadership is reinforced by the breadth of its Vicryl, PDS, Monocryl, and STRATAFIX franchises and by long-standing clinical relationships across hospital and ASC accounts. Recent FDA clearances for antimicrobial and knotless configurations demonstrate continued investment in differentiated closure technologies that can support formulary retention beyond price competition ^{[3]U.S. Food and Drug Administration. “510(k) Premarket Notification Database.” fda.gov}.

B. Braun (Aesculap)

B. Braun's Aesculap division held approximately 13.5% of the global market in 2025. Aesculap has particular strength in European hospital systems and high-specification surgical settings. Its acquisition of True Digital Surgery broadened the company's digital surgical ecosystem in neurosurgery, spinal surgery, and ENT, creating adjacent clinical touchpoints that can reinforce specialist account relationships ^{[5]B. Braun. “B. Braun Acquires True Digital Surgery.” bbraun.com}.

Medtronic

Medtronic held approximately 8.0% of the global market in 2025. Medtronic's suture presence is most closely linked to specialty surgical teams, particularly in cardiovascular and neurological applications. Its wider device relationships can support protocol-based purchasing and create meaningful barriers to displacement in accounts where product decisions are integrated across procedural categories.

Corza Medical

Corza Medical competes through dedicated surgical portfolios spanning ophthalmic, specialty, and general applications. The company's expanded Onatec ophthalmic portfolio demonstrates a focus on precision-driven surgical niches in which needle design, material handling, and institutional familiarity carry considerable weight. Such specialization can offset the scale advantages of broader suture manufacturers ^{[6]Corza Medical. “Corza Medical Announces the Launch of the Expanded Onatec Ophthalmic Suture Portfolio.” corza.com}.

CONMED

CONMED participates through a surgical specialty portfolio serving hospital and ASC customers. Its competitive position is supported by bundled relationships in general surgery, arthroscopy, and related procedural categories. Absorbable sutures can benefit from those integrated accounts where purchasers prioritize supplier consolidation and dependable access to complementary surgical products.

Advanced Medical Solutions

Advanced Medical Solutions has strengthened its surgical-closure position through the integration of Peters Surgical. The expanded platform combines specialty sutures, haemostasis products, tissue adhesives, manufacturing capability, and European commercial access. This creates a more credible alternative for customers seeking focused wound-closure expertise beyond the largest global suppliers.

Demetech

Demetech addresses value-oriented procurement channels with absorbable and non-absorbable suture offerings. Its positioning depends on cost competitiveness, production reliability, and distributor access in GPO, surgery-center, and international markets. This model is particularly relevant where hospitals seek qualified alternatives without sacrificing supply consistency.

Futura Surgicare

Futura Surgicare markets surgical sutures internationally under the Dolphin Sutures brand. The company's export-oriented model supports its role as a cost-competitive supplier in markets where multinational products face affordability constraints. Distribution partnerships are essential to translating manufacturing capability into durable hospital and ASC access.

Genesis MedTech

Genesis MedTech serves China's domestic medical-device market with resorbable suture capabilities. Its local-market presence and regulatory familiarity support competition in cost-sensitive hospital segments. Building broader international access will depend on expanding registrations and demonstrating quality consistency across diverse clinical settings.

Healthium Medtech

Healthium Medtech maintains a comprehensive suture portfolio across India and export markets. Its manufacturing base and domestic clinical relationships position the company as a significant alternative in Indian public procurement, while its international reach supports participation in other price-conscious markets across Asia, Africa, and the Middle East.

Integra Lifesciences

Integra Lifesciences participates through specialty neurosurgical and regenerative-medicine applications. Its relevance in the suture market is connected to procedure-specific supply configurations and established neurosurgical relationships. This focus supports a differentiated position in settings where dural repair and related products are specified alongside closure requirements.

Lotus Surgicals

Lotus Surgicals supplies a broad absorbable-suture range to domestic and export markets. Its competitive opportunity lies in cost-sensitive hospital channels, supported by regulatory filings and distribution access across Asian and Middle Eastern markets. Affordability and product availability remain central to its value proposition.

Unisur

Unisur provides absorbable surgical sutures for hospital and clinic customers across Africa and Asia. The company addresses an important access-oriented segment in which public purchasers seek dependable, affordable surgical supplies. Its competitive relevance depends on local distribution strength and the ability to meet routine clinical requirements consistently.

Vital Sutures

Vital Sutures competes through accessible absorbable and non-absorbable products in emerging markets. The company is positioned to address affordability gaps where premium multinational brands are less viable for routine public-sector purchasing. Maintaining quality assurance and supply reliability is central to its standing in these procurement environments.

Vitrex Medical Group

Vitrex Medical Group participates through medical-device manufacturing and distribution operations. Absorbable sutures form part of a broader surgical-disposables offering, allowing the company to serve hospital accounts through portfolio breadth and established European distribution relationships. Its position is strongest where buyers value consolidated supply of routine clinical consumables.

Recent Industry Developments

B. Braun SE Completes Full Acquisition of True Digital Surgery

B. Braun completed its acquisition of True Digital Surgery in September 2025, integrating digital robotic-assisted 3D surgical microscopy capabilities into the Aesculap surgical ecosystem. The transaction expands B. Braun's presence in neurosurgery, spinal surgery, and ENT environments, where clinical technology relationships may reinforce demand for associated surgical products ^{[5]B. Braun. “B. Braun Acquires True Digital Surgery.” bbraun.com}.

Corza Medical Launches Expanded Onatec Ophthalmic Suture Portfolio

Corza Medical launched its expanded Onatec Ophthalmic Suture Portfolio in July 2025. The offering spans nearly 130 absorbable and non-absorbable products for ophthalmic and oculoplastic procedures, strengthening Corza's specialist position in a segment where precision needle geometry and material handling are critical purchasing considerations ^{[6]Corza Medical. “Corza Medical Announces the Launch of the Expanded Onatec Ophthalmic Suture Portfolio.” corza.com}.